| Literature DB >> 33762374 |
Jonathan P Segal1, Jean-Frédéric LeBlanc2, Ailsa L Hart3.
Abstract
Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing and improvement in a patient's quality of life. 5-aminosalicylate acid medications remain the first-line treatment for mild to moderate disease. In the event of suboptimal response to these medications, escalation to immunosuppressive medications and biologics may be necessary. Importantly, despite best medical therapy, surgery may be required in a proportion of patients. The future will likely see an array of new therapeutic options for those with ulcerative colitis with the potential for a more personalised treatment approach. © Royal College of Physicians 2021. All rights reserved.Entities:
Keywords: biologics; inflammatory bowel disease; ulcerative colitis
Mesh:
Year: 2021 PMID: 33762374 PMCID: PMC8002778 DOI: 10.7861/clinmed.2021-0080
Source DB: PubMed Journal: Clin Med (Lond) ISSN: 1470-2118 Impact factor: 2.659